Here, we represent a new strategy for combating oncogenic RAS-ERK signaling pathway by targeting the PHB-CRAF interaction in pancreatic ductal adenocarcinoma. This evidence concerns the gene MAPK1 and pancreatic ductal adenocarcinoma.